New antifungal treatment targeting specific fungal infections
Targeted Pan-Antifungal Liposomes
This study is exploring a new way to deliver antifungal medicines directly to harmful fungi that can make people with weakened immune systems, like those with HIV, very sick, hoping to make treatments more effective and safer for patients.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Georgia NIH-funded |
| Lab location | 1 site (Athens, United States) |
| Project ID | NIH-11019763 on NIH RePORTER |
What this research studies
This research focuses on developing a novel method to deliver antifungal drugs directly to the cell walls of harmful fungi, such as Aspergillus fumigatus, which can cause severe infections in individuals with weakened immune systems, particularly those with HIV. By using targeted liposomes, the approach aims to enhance the effectiveness of existing antifungal medications while minimizing toxicity to human organs. The research addresses the urgent need for better treatments for invasive fungal diseases, which currently have high mortality rates and limited therapeutic options.
Who could benefit from this research
Good fit: Ideal candidates for this research include individuals with compromised immune systems, such as those living with HIV or those undergoing stem cell or organ transplants.
Not a fit: Patients with healthy immune systems or those not at risk for invasive fungal infections may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could significantly improve survival rates and treatment outcomes for patients suffering from life-threatening fungal infections.
How similar studies have performed: While the approach of targeted drug delivery is promising, it is relatively novel in the context of antifungal therapies, and similar strategies have shown success in other areas of medicine.
Where this research is happening
Athens, United States
- University of Georgia — Athens, United States (Active)
Researchers
- Principal investigator: Meagher, Richard Brian — University of Georgia
- Study coordinator: Meagher, Richard Brian
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.